Q-omics provides the consensus-scored MIR4665 profile across patient tissues and cancer cell-line models. MIR4665 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR4665 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, MIR4665 RNA expression shows 9,776 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, COAD, and THYM as cancer lineages where MIR4665 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4665 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4665 survival associations across molecular data types. MIR4665 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4665 RNA expression–survival associations across cancer types. High MIR4665 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in ESCA, GBM and STAD. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR4665 RNA expression.
This table summarizes MIR4665 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4665. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4665 shows lower tumor expression in KIRC and higher tumor expression in COAD, STAD, LIHC and LUSC. The COAD box plot shows higher MIR4665 RNA expression in tumor versus normal tissue (log2 FC = +0.508, t-test p = .003).
This table shows molecular features associated with MIR4665 in patient tissues and cancer cell lines. In patient samples, MIR4665 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
